Copy number variation analysis using next-generation sequencing identifies the CFHR3/CFHR1 deletion in atypical hemolytic uremic syndrome: a case report

References

• Taylor CM, Chua C, Howie AJ, et al. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004;19:419–425.
   PubMed Web of Science ®Google Scholar
• Maga TK, Nishimura CJ, Weaver AE, et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31:E1445–E1460.
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554–562.
   PubMed Web of Science ®Google Scholar
• Francis NJ, McNicholas B, Awan A, et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood. 2012;119:591–601.
   PubMed Web of Science ®Google Scholar
• Díaz-Guillén MA, Rodríguez de Córdoba S, Heine-Suñer D. A radiation hybrid map of complement factor H and factor H-related genes. Immunogenetics. 1999;49:549–552.
   PubMed Web of Science ®Google Scholar
• Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–1859.
   PubMed Web of Science ®Google Scholar
• Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35:421–447.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24:492–495.
   PubMed Web of Science ®Google Scholar
• Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67:31–42.
   PubMed Web of Science ®Google Scholar
• Holmes LV, Strain L, Staniforth SJ, et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One. 2013;8:e60352, 1–7.
   PubMed Web of Science ®Google Scholar
• Moreno-Cabrera JM, Del Valle J, Castellanos E, et al. Evaluation of CNV detection tools for NGS panel data in genetic diagnostics. Eur J Hum Genet. 2020;28:1645–1655.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3:e41.
   PubMed Web of Science ®Google Scholar
• Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379–387.
   PubMed Web of Science ®Google Scholar
• Ellingford JM, Campbell C, Barton S, et al. Validation of copy number variation analysis for next-generation sequencing diagnostics. Eur J Hum Genet. 2017;25:719–724.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Amr SS, Bowser MJ, et al. Viscap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data. Genet Med. 2016;18:712–719.
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Wiech T, Stea ED, et al. CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol. 2020;31:241–256.
   PubMed Web of Science ®Google Scholar
• Yao R, Yu T, Qing Y, et al. Evaluation of copy number variant detection from panel-based next-generation sequencing data. Mol Genet Genomic Med. 2019;7:e00513.
   PubMed Web of Science ®Google Scholar
• Bu F, Borsa NG, Jones MB, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol. 2016;27:1245–1253.
   PubMed Web of Science ®Google Scholar
• Gaut JP, Jain S, Pfeifer JD, et al. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol. 2017;30:1739–1747.
   PubMedGoogle Scholar
• Thergaonkar RW, Narang A, Gurjar BS, et al. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol. 2018;22:653–660.
   PubMed Web of Science ®Google Scholar
• Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111:1512–1514.
   PubMed Web of Science ®Google Scholar
• Speth C, Rambach G, Würzner R, et al. Complement and platelets: mutual interference in the immune network. Mol Immunol. 2015;67:108–118.
   PubMed Web of Science ®Google Scholar
• Fujisawa M, Yasumoto A, Kato H, et al. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haematol. 2020;189:182–186.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kwak SH, Shin JI, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res. 2009;66:336–340.
   PubMed Web of Science ®Google Scholar
• Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61:289–299.
   PubMed Web of Science ®Google Scholar
• Wijnsma KL, Duineveld C, Wetzels JFM, et al. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34:2261–2277.
   PubMed Web of Science ®Google Scholar
• Dedhia P, Govil A, Mogilishetty G, et al. Eculizumab and belatacept for De novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: A case report. Transplant Proc. 2017;49:188–192.
   PubMed Web of Science ®Google Scholar
• Nozawa A, Ozeki M, Hori T, et al. A heterozygous CFHR3-CFHR1 gene deletion in a pediatric patient With transplant-associated thrombotic microangiopathy Who was treated With eculizumab. J Pediatr Hematol Oncol. 2018;40:e544–e5e6.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–2181.
   PubMed Web of Science ®Google Scholar
• Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-Arm, open-label trial. Am J Kidney Dis. 2016;68:84–93.
   PubMed Web of Science ®Google Scholar
• Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12:1938–1944.
   PubMed Web of Science ®Google Scholar
• Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008;23:1517–1521.
   PubMed Web of Science ®Google Scholar